Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men

World Journal of Urology

Volumn 25, Issue 1, 2007, Pages 95-103

  Stephan, Carsten ^a   Xu, Chuanliang ^a,b   Cammann, Henning ^a   Graefen, Markus ^c   Haese, Alexander ^c   Huland, Hartwig ^c   Semjonow, Axel ^d   Diamandis, Eleftherios P ^e   Remzi, Mesut ^f   Djavan, Bob ^f   Wildhagen, Mark F ^g   Blijenberg, Bert G ^g   Finne, Patrik ^h   Stenman, Ulf Hakan ^h   Jung, Klaus ^a   Meyer, Hellmuth Alexander ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e MOUNT SINAI HOSPITAL   (Canada)

^f Urologische Universitatsklinik   (Austria)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Artificial neural network; Prostate biopsy; Prostate cancer; Prostate specific antigen; Receiver operating characteristic curve

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; BLOOD; COMPARATIVE STUDY; HUMAN; INSTRUMENTATION; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR; RISK FACTOR; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33947431997     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-006-0132-9     Document Type: Article

References (40)

1. Polascik TJ, Oesterling JE, Partin AW (1999) Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 162:293-306
2. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350:2239-2246
3. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T (1991) Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37:1618-1625
4. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O (1991) A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222-226
5. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 279:1542-1547
6. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW (1996) Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology 48:55-61
7. Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening SA, Jung K (2005) The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of <4 ng/mL. Cancer 104:993-1003
8. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, Woodrum DL (1999) Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model. Urology 54:220-224
9. Jung K, Stephan C, Elgeti U, Lein M, Brux B, Kristiansen G, Rudolph B, Hauptmann S, Schnorr D, Loening SA (2001) Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 μg/l - are they useful tools for early detection and screening of prostate cancer? Int J Cancer 93:759-765
10. Lee CT, Scardino PT (2001) Percent free Prostate-specific antigen for first-time prostate biopsy. Urology 57:594-598
11. Stephan C, Lein M, Jung K, Schnorr D, Loening SA (1997) Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies? [Letter]. J Urol 157:1371
12. Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H (1997) Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol 158:2188-2192
13. Mettlin C, Chesley AE, Murphy GP, Bartsch G, Toi A, Bahnson R, Church P (1999) Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer. Prostate 39:153-158
14. Stephan C, Lein M, Jung K, Schnorr D, Loening SA (1997) The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 79:104-109
15. Lein M, Koenig F, Jung K, McGovern FJ, Skates SJ, Schnorr D, Loening SA (1998) The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: Establishment of reference ranges in a large population of healthy men. Br J Urol 82:231-236
16. Carlson GD, Calvanese CB, Partin AW (1998) An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: Results on 4298 cases. Urology 52:455-461
17. Virtanen A, Gomari M, Kranse R, Stenman UH (1999) Estimation of prostate cancer probability by logistic regression: Free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 45:987-994
18. Babaian RJ, Fritsche H, Ayala A, Bhadkamkar V, Johnston DA, Naccarato W, Zhang Z (2000) Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/ ml. Urology 56:1000-1006
19. Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M (2002) Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 20:921-929
20. Finne P, Finne R, Auvinen A, Juusela H, Aro J, Maattanen L, Hakama M, Rannikko S, Tammela TL, Stenman U (2000) Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 56:418-422
21. Remzi M, Anagnostou T, Ravery V, Zlotta A, Stephan C, Marberger M, Djavan B (2003) An artificial neural network to predict the outcome of repeat prostate biopsies. Urology 62:456-460
22. Stephan C, Jung K, Cammann H, Vogel B, Brux B, Kristiansen G, Rudolph B, Hauptmann S, Lein M, Schnorr D, Sinha P, Loening SA (2002) An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: Results of a 5-year investigation. Int J Cancer 99:466-473
23. Kalra P, Togami J, Bansal BSG, Partin AW, Brawer MK, Babaian RJ, Ross LS, Niederberger CS (2003) A neurocomputational model for prostate carcinoma detection. Cancer 98:1849-1854
24. Partin AW, Murphy GP, Brawer MK (2000) Report on prostate cancer tumor marker workshop 1999. Cancer 88:955-963
25. Jung K, Stephan C, Lein M, Henke W, Schnorr D, Brux B, Schürenkämper P, Loening SA (1996) Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 42:1026-1033
26. Oberpenning F, Weining C, Brandt B, De Angelis G, Heinecke A, Hamm M, Stieber P, Hertle L, Schmid HP, Semjonow A (2002) Combining free and total prostate specific antigen assays from different manufacturers: The pitfalls. Eur Urol 42:577-582
27. Patel D, White PA, Milford WA (2000) A comparison of six commercial assays for total and free prostate specific antigen (PSA): The predictive value of the ratio of free to total PSA. BJU Int 85:686-689
28. Semjonow A, Oberpenning F, Brandt B, Zechel C, Brandau W, Hertle L (1996) Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 48(Suppl):10-15
29. Yurdakul G, Bangma C, Blijenberg B, van Zelst B, Wildhagen M, van der KT, Schroder F (2002) Different PSA assays lead to detection of prostate cancers with identical histological features. Eur Urol 42:154-158
30. Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LFA, Lein M, Sinha P, Loening SA, Jung K (2002) Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 48:1279-1287
31. Hodge KK, McNeal JE, Terris MK, Stamey TA (1989) Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142:71-74
32. Romics I (2004) The technique of ultrasound guided prostate biopsy. World J Urol 22:353-356
33. Woodrum D, York L (1998) Two-year stability of free and total PSA in frozen serum samples. Urology 52:247-251
34. Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schroder FH (2001) Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 88:545-550
35. Jung K, Stephan C, Lein M, Brux B, Sinha P, Schnorr D, Loening SA (2001) Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms - What has to be considered? Prostate 46:307-310
36. Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA (2000) Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 9:1133-1147
37. Schroder FH, Kranse R (2003) Verification bias and the prostate-specific antigen test - is there a case for a lower threshold for biopsy? N Engl J Med 349:393-395
38. Roehl KA, Antenor JA, Catalona WJ (2002) Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J Urol 168:922-925
39. Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L (1996) Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl 7:3-16
40. Sargent DJ (2001) Comparison of artificial neural networks with other statistical approaches. Cancer 91:1636-1642